Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 625Stomach Neoplasms 75Neoplasm Metastasis 59Neoplasms 39HER2-positive Breast Cancer 33Breast Neoplasms, Male 30Colorectal Neoplasms 28Brain Neoplasms 25Carcinoma, Non-Small-Cell Lung 21Inflammatory Breast Neoplasms 20Esophageal Neoplasms 20Pancreatic Neoplasms 13Triple Negative Breast Neoplasms 12Lung Neoplasms 11Endometrial Neoplasms 11Ovarian Neoplasms 10Colonic Neoplasms 10Urinary Bladder Neoplasms 9Rectal Neoplasms 9Prostatic Neoplasms 9Cardiotoxicity 8Adenocarcinoma 8Salivary Gland Neoplasms 7Gallbladder Neoplasms 7Breast Diseases 7Biliary Tract Neoplasms 7Adenocarcinoma Of Esophagus 7Uterine Cervical Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Sarcoma 6

Interventions

pyrotinib 2Surgical Procedures, Operative 2pertuzumab 1Trastuzumab 1Neoadjuvant Therapy 1Mastectomy 1Leuprolide 1Goserelin 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Cancer Invasive × Trastuzumab × Clear all
NCT04398914 2022-03-31

Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

Shanghai Jiao Tong University School of Medicine

Phase 2 Active not recruiting
216 enrolled
Breast

Breast Cancer Invasive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡